{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:10:26Z","timestamp":1793247026964,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,8,17]],"date-time":"2017-08-17T00:00:00Z","timestamp":1502928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1038\/npp.2017.177","type":"journal-article","created":{"date-parts":[[2017,8,17]],"date-time":"2017-08-17T07:01:22Z","timestamp":1502953282000},"page":"503-512","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":131,"title":["Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results"],"prefix":"10.1038","volume":"43","author":[{"name":"FragXis Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriene A","family":"Youssef","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Berry-Kravis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Czech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randi J","family":"Hagerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hessl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin Y","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rabbia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Deptula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Kinch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Drewitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lothar","family":"Lindemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Marcinowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Langland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Fontoura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Santarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge A","family":"Quiroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,17]]},"reference":[{"key":"BFnpp2017177_CR1","first-page":"485","volume":"89","author":"MG Aman","year":"1985","unstructured":"Aman MG, Singh NN, Stewart AW, Field CJ (1985). The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 89: 485\u2013491.","journal-title":"Am J Ment Defic"},{"key":"BFnpp2017177_CR2","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.tins.2004.04.009","volume":"27","author":"MF Bear","year":"2004","unstructured":"Bear MF, Huber KM, Warren ST (2004). The mGluR theory of fragile X mental retardation. Trends Neurosci 27: 370\u2013377.","journal-title":"Trends Neurosci"},{"key":"BFnpp2017177_CR3","doi-asserted-by":"publisher","first-page":"321ra325","DOI":"10.1126\/scitranslmed.aab4109","volume":"8","author":"E Berry-Kravis","year":"2016","unstructured":"Berry-Kravis E, Des Portes V, Hagerman R, Jacquemont S, Charles P, Visootsak J et al (2016). Mavoglurant in fragile X syndrome: results of two randomized, double-blind, placebo-controlled trials. Sci Transl Med 8: 321ra325.","journal-title":"Sci Transl Med"},{"key":"BFnpp2017177_CR4","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1097\/DBP.0b013e31829d1f20","volume":"34","author":"E Berry-Kravis","year":"2013","unstructured":"Berry-Kravis E, Hessl D, Abbeduto L, Reiss AL, Beckel-Mitchener A, Urv TK (2013). Outcome measures for clinical trials in fragile X syndrome. J Dev Behav Pediatr 34: 508\u2013522.","journal-title":"J Dev Behav Pediatr"},{"key":"BFnpp2017177_CR5","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1136\/jmg.2008.063701","volume":"46","author":"E Berry-Kravis","year":"2009","unstructured":"Berry-Kravis E, Hessl D, Coffey S, Hervey C, Schneider A, Yuhas J et al (2009). A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet 46: 266\u2013271.","journal-title":"J Med Genet"},{"key":"BFnpp2017177_CR6","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1089\/cap.2006.16.525","volume":"16","author":"E Berry-Kravis","year":"2006","unstructured":"Berry-Kravis E, Krause SE, Block SS, Guter S, Wuu J, Leurgans S et al (2006). Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. J Child Adol Psychop 16: 525\u2013540.","journal-title":"J Child Adol Psychop"},{"key":"BFnpp2017177_CR7","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1146\/annurev-neuro-060909-153138","volume":"35","author":"AL Bhakar","year":"2012","unstructured":"Bhakar AL, Dolen G, Bear MF (2012). The pathophysiology of fragile X (and what it teaches us about synapses). Annu Rev Neurosci 35: 417\u2013443.","journal-title":"Annu Rev Neurosci"},{"key":"BFnpp2017177_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2190\/2DKF-292P-A53W-W0A8","volume":"43","author":"MS Caserta","year":"1996","unstructured":"Caserta MS, Lund DA, Wright SD (1996). Exploring the Caregiver Burden Inventory (CBI): further evidence for a multidimensional view of burden. Int J Aging Hum Dev 43: 21\u201334.","journal-title":"Int J Aging Hum Dev"},{"key":"BFnpp2017177_CR9","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1023\/A:1025014929212","volume":"33","author":"JN Constantino","year":"2003","unstructured":"Constantino JN, Davis SA, Todd RD, Schindler MK, Gross MM, Brophy SL et al (2003). Validation of a brief quantitative measure of autistic traits: comparison of the social responsiveness scale with the autism diagnostic interview-revised. J Autism Dev Disord 33: 427\u2013433.","journal-title":"J Autism Dev Disord"},{"key":"BFnpp2017177_CR10","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.neuron.2007.12.001","volume":"56","author":"G Dolen","year":"2007","unstructured":"Dolen G, Osterweil E, Rao BS, Smith GB, Auerbach BD, Chattarji S et al (2007). Correction of fragile X syndrome in mice. Neuron 56: 955\u2013962.","journal-title":"Neuron"},{"key":"BFnpp2017177_CR11","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1023\/B:JADD.0000005999.27178.55","volume":"33","author":"AJ Esbensen","year":"2003","unstructured":"Esbensen AJ, Rojahn J, Aman MG, Ruedrich S (2003). Reliability and validity of an assessment instrument for anxiety, depression, and mood among individuals with mental retardation. J Autism Dev Disord 33: 617\u2013629.","journal-title":"J Autism Dev Disord"},{"key":"BFnpp2017177_CR12","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"W Guy","year":"1976","unstructured":"Guy W (1976) ECDEU Assessment Manual for Psychopharmacology. U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs: Rockville, Maryland."},{"key":"BFnpp2017177_CR13","doi-asserted-by":"publisher","first-page":"e294","DOI":"10.4088\/JCP.13r08714","volume":"75","author":"RJ Hagerman","year":"2014","unstructured":"Hagerman RJ, Des-Portes V, Gasparini F, Jacquemont S, Gomez-Mancilla B (2014). Translating molecular advances in fragile X syndrome into therapy: a review. J Clin Psychiatry 75: e294\u2013e307.","journal-title":"J Clin Psychiatry"},{"key":"BFnpp2017177_CR14","doi-asserted-by":"publisher","first-page":"7746","DOI":"10.1073\/pnas.122205699","volume":"99","author":"KM Huber","year":"2002","unstructured":"Huber KM, Gallagher SM, Warren ST, Bear MF (2002). Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci USA 99: 7746\u20137750.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFnpp2017177_CR15","doi-asserted-by":"publisher","first-page":"64ra61","DOI":"10.1126\/scitranslmed.3001708","volume":"3","author":"S Jacquemont","year":"2011","unstructured":"Jacquemont S, Curie A, des Portes V, Torrioli MG, Berry-Kravis E, Hagerman RJ et al (2011). Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med 3: 64ra61.","journal-title":"Sci Transl Med"},{"key":"BFnpp2017177_CR16","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1021\/jm501642c","volume":"58","author":"G Jaeschke","year":"2015","unstructured":"Jaeschke G, Kolczewski S, Spooren W, Vieira E, Bitter-Stoll N, Boissin P et al (2015). Metabotropic glutamate receptor 5 negative allosteric modulators: discovery of 2-chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (Basimglurant, RO4917523), a promising novel medicine for psychiatric diseases. J med chem 58: 1358\u20131371.","journal-title":"J med chem"},{"key":"BFnpp2017177_CR17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1146\/annurev-med-061109-134644","volume":"62","author":"DD Krueger","year":"2011","unstructured":"Krueger DD, Bear MF (2011). Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annu Rev Med 62: 411\u2013429.","journal-title":"Annu Rev Med"},{"key":"BFnpp2017177_CR18","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1093\/nar\/29.11.2276","volume":"29","author":"Z Li","year":"2001","unstructured":"Li Z, Zhang Y, Ku L, Wilkinson KD, Warren ST, Feng Y (2001). The fragile X mental retardation protein inhibits translation via interacting with mRNA. Nucleic Acids Res 29: 2276\u20132283.","journal-title":"Nucleic Acids Res"},{"key":"BFnpp2017177_CR19","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1124\/jpet.111.185660","volume":"339","author":"L Lindemann","year":"2011","unstructured":"Lindemann L, Jaeschke G, Michalon A, Vieira E, Honer M, Spooren W et al (2011). CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor. J Pharmacol Exp Ther 339: 474\u2013486.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFnpp2017177_CR20","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1124\/jpet.114.222463","volume":"353","author":"L Lindemann","year":"2015","unstructured":"Lindemann L, Porter RH, Scharf SH, Kuennecke B, Bruns A, von Kienlin M et al (2015). Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression. J Pharmacol Exp Ther 353: 213\u2013233.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFnpp2017177_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neuron.2012.03.009","volume":"74","author":"A Michalon","year":"2012","unstructured":"Michalon A, Sidorov M, Ballard TM, Ozmen L, Spooren W, Wettstein JG et al (2012). Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 74: 49\u201356.","journal-title":"Neuron"},{"key":"BFnpp2017177_CR22","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1124\/jpet.105.089839","volume":"315","author":"RH Porter","year":"2005","unstructured":"Porter RH, Jaeschke G, Spooren W, Ballard TM, Buttelmann B, Kolczewski S et al (2005). Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J Pharmacol Exp Ther 315: 711\u2013721.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFnpp2017177_CR23","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1001\/jamapsychiatry.2016.0838","volume":"73","author":"JA Quiroz","year":"2016","unstructured":"Quiroz JA, Tamburri P, Deptula D, Banken L, Beyer U, Rabbia M et al (2016). Efficacy and safety of basimglurant as adjunctive therapy for major depression: a randomized clinical trial. JAMA Psychiatr 73: 675\u2013684.","journal-title":"JAMA Psychiatr"},{"key":"BFnpp2017177_CR24","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1076\/jcen.20.3.310.823","volume":"20","author":"C Randolph","year":"1998","unstructured":"Randolph C, Tierney MC, Mohr E, Chase TN (1998). The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 20: 310\u2013319.","journal-title":"J Clin Exp Neuropsychol"},{"key":"BFnpp2017177_CR25","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.jaac.2011.04.004","volume":"50","author":"BR Rutherford","year":"2011","unstructured":"Rutherford BR, Sneed JR, Tandler JM, Rindskopf D, Peterson BS, Roose SP (2011). Deconstructing pediatric depression trials: an analysis of the effects of expectancy and therapeutic contact. J Am Acad Child Adolesc Psychiatry 50: 782\u2013795.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"BFnpp2017177_CR26","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s10803-011-1370-2","volume":"42","author":"SM Sansone","year":"2012","unstructured":"Sansone SM, Widaman KF, Hall SS, Reiss AL, Lightbody A, Kaufmann WE et al (2012). Psychometric study of the Aberrant Behavior Checklist in Fragile X Syndrome and implications for targeted treatment. J Autism Dev Disord 42: 1377\u20131392.","journal-title":"J Autism Dev Disord"},{"key":"BFnpp2017177_CR27","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.coph.2014.11.004","volume":"20C","author":"SH Scharf","year":"2015","unstructured":"Scharf SH, Jaeschke G, Wettstein JG, Lindemann L (2015). Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome. Curr Opin Pharmacol 20C: 124\u2013134.","journal-title":"Curr Opin Pharmacol"},{"key":"BFnpp2017177_CR28","volume-title":"Vineland Adaptive Behavior Scales","author":"SS Sparrow","year":"2005","unstructured":"Sparrow SS, Cicchetti DV, Balla DA (2005) Vineland Adaptive Behavior Scales, 2nd edn. The Psychological Corporation: San Antonio."},{"key":"BFnpp2017177_CR29","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1056\/NEJM199912093412412","volume":"341","author":"FR Volkmar","year":"1999","unstructured":"Volkmar FR (1999). Lessons from secretin. N Engl J Med 341: 1842\u20131844.","journal-title":"N Engl J Med"},{"key":"BFnpp2017177_CR30","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.1016\/j.bmc.2014.09.033","volume":"22","author":"I Vranesic","year":"2014","unstructured":"Vranesic I, Ofner S, Flor PJ, Bilbe G, Bouhelal R, Enz A et al (2014). AFQ056\/mavoglurant, a novel clinically effective mGluR5 antagonist: identification, SAR and pharmacological characterization. Bioorg Med Chem 22: 5790\u20135803.","journal-title":"Bioorg Med Chem"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/npp2017177.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/npp2017177","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/npp.2017.177","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/npp2017177.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T19:58:07Z","timestamp":1684439887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/npp2017177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,17]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["BFnpp2017177"],"URL":"https:\/\/doi.org\/10.1038\/npp.2017.177","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,17]]},"assertion":[{"value":"13 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}